Background Once castration resistance is documented and secondary hormone therapy is
ineffective, standard treatment of metastatic prostate cancer is docetaxel, with …

Docetaxel (Taxotere®) is a well established anti-mitotic chemotherapy agent. Among other
therapeutic indications, docetaxel plus prednisone is indicated for first-line chemotherapy in …

Objectives: Favorable phase I results justified this pilot phase II study to assess the efficacy
of docetaxel/curcumin in patients with chemotherapy-naive metastatic castration-resistant …

Background Ethnic differences in drug susceptibility and toxicity are a major concern, not
only in drug development but also in the clinical setting. We review the toxicity profiles of …

What's known on the subject? and What does the study add? Estramustine phosphate has
anti‐tumour properties and it improves patient outcomes if combined with other …

Androgen deprivation is the therapy of choice in the majority of patients with metastatic
prostate cancer. However, a state of castration resistance ultimately occurs after hormone …

Docetaxel‐based therapy is established as the standard first‐line chemotherapy in patients
with metastatic castration‐resistant prostate cancer (mCRPC), based on results from two …

Bark extracts from the Amazonian rain forest tree Geissospermum vellosii (pao pereira),
enriched in α-carboline alkaloids have significant anticancer activities in certain preclinical …

Objectives To retrospectively review the oncologic outcomes of docetaxel-based
chemotherapy in Japanese men with metastatic castration-resistant prostate cancer …

Background: Recently, increasing relevant studies researched the efficacy of castration
resistant prostate cancer (CRPC) patients using chemotherapy with or without estramustine …